ETON 17.67 ▼ -1.12% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Eton Pharmaceuticals Inc.

    NASDAQ: ETON · Real-Time Price · USD
    17.67
    -0.20 (-1.12%)
    At close: Sep 05, 2025, 3:59 PM
    17.67
    0.00%
    After-hours: Sep 05, 2025, 04:42 PM EDT
    -1.12%
    Bid 16.51
    Market Cap 473.87M
    Revenue (ttm) 58.18M
    Net Income (ttm) -4.13M
    EPS (ttm) -0.15
    PE Ratio (ttm) -117.8
    Forward PE 16.94
    Analyst Strong Buy
    Ask 18.34
    Volume 277,924
    Avg. Volume (20D) 449,695
    Open 18.08
    Previous Close 17.87
    Day's Range 17.39 - 18.32
    52-Week Range 4.52 - 21.48
    Beta 1.14

    About ETON

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol ETON
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for ETON stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Eton Pharmaceuticals Inc. is scheduled to release its earnings on Nov 11, 2025, during market hours.
    Analysts project revenue of ... Unlock content with Pro Subscription
    4 weeks ago
    +0%
    Eton Pharmaceuticals shares are trading higher aft... Unlock content with Pro Subscription
    1 month ago
    +9.8%
    Eton Pharmaceuticals shares are trading higher after the company announced the FDA has accepted its new drug application for ET-600.
    news image

    4 weeks ago · seekingalpha.com

    Eton Pharmaceuticals, Inc. (ETON) Q2 2025 Earnings Call Transcript

    Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants David C. Krempa - Chief Business Officer James R.

    news image

    4 weeks ago · seekingalpha.com

    Eton Pharmaceuticals: Growth At A Reasonable Price, Or Maybe Even Better With Options

    Eton Pharmaceuticals offers GARP potential, focusing on ultra-rare disease drugs acquired at low cost, with a lean, specialized sales force and positive cash flow. My DCF model shows 80%-87% upside to...

    news image

    4 weeks ago · zacks.com

    Eton Pharmaceuticals, Inc. (ETON) Reports Q2 Loss, Tops Revenue Estimates

    Eton Pharmaceuticals, Inc. (ETON) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.12 per share a year ago.

    news image

    4 weeks ago · fool.com

    Eton (ETON) Q2 Revenue Jumps 108%

    Eton Pharmaceuticals (ETON), a biopharmaceutical company focused on rare diseases, posted earnings for Q2 2025 on August 7, 2025. The main highlight was a strong revenue increase from both core and re...

    news image

    1 month ago · zacks.com

    Eton Pharmaceuticals, Inc. (ETON) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    Eton Pharmaceuticals (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    news image

    1 month ago · seekingalpha.com

    Eton Pharma Near Term Catalysts Vanish

    Important near-term catalysts for ETON have been eliminated due to insider stock sales and a disappointing partial FDA approval for their new drug, Khindivi. Insider sales by the CEO and CBO after Q1 ...

    news image

    3 months ago · seekingalpha.com

    Eton Pharmaceuticals: Rapid Revenue Growth And Pipeline Catalysts Point To More Upside

    Eton Pharmaceuticals is experiencing explosive rare-disease revenue growth, with a 117% YoY increase and a robust pipeline fueling future expansion. Despite a 400% share price surge, ETON remains attr...

    Add to Watchlist